Login to Your Account

In The Clinic NEWS

Phase II results with oral ridinilazole against the potentially lethal Clostridium difficile bug "exceeded our wildest expectations" said Glyn Edwards, CEO of Oxford, U.K.-based Summit Therapeutics plc, which is working on the phase III program's design as partnership talks continue.

AASLD 2015

SAN FRANCISCO – New clinical data from Gilead Sciences Inc. and Bristol-Myers Squibb Co, presented at the AASLD Annual Meeting added support to the drugmakers' cases for the efficacy of therapeutic combinations capable of battling HCV.

With a "groundwork of foundational support" for Aerosurf from top-line phase IIa data plus previous work, Discovery Laboratories Inc. is going into phase IIb development of the aerosolized KL4 surfactant for preventing RDS in premature infants, CEO John Cooper said.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: